WHO ICTRP trial
Investigating the effect of resveratrol on polycystic ovary syndrome
IRCT20221106056417N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20221106056417N1 |
|---|---|
| Public title | Investigating the effect of resveratrol on polycystic ovary syndrome |
| Scientific title | Investigating the effect of resveratrol administration on the expression of factors involved in mitochondrial function and biogenesis in granulosa cells of patients with PCOS who are candidates for ART: a three-blind randomized controlled clinical trial |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Polycystic ovary syndrome. Polycystic ovary syndrome;E28.2 |
| Interventions | Intervention group: use of resveratrol. In this group of patients, for 60 days until puncture, they take two capsules of 800 mg of resveratrol daily, twice in the morning and in the evening. Their routine treatment, including metformin, is… |
| Registration date | Feb 9, 2023 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: